Document 0796
 DOCN  M94B0796
 TI    Chemotherapy associated with zidovudine and Gm-CSF in human
       immunodeficiency virus-related non-Hodgkin's lymphoma (HIV-NHL) (Meeting
       abstract).
 DT    9412
 AU    Gabarre J; Lepage E; Thyss A; Bastion Y; Sebban C; Schlaifer D; Ribrag
       V; Fereres M; Raphael M; Gisselbrecht C; GELA, Saint-Louis Hosp., Paris,
       France
 SO    Proc Annu Meet Am Assoc Cancer Res; 35:A1138 1994. Unique Identifier :
       AIDSLINE ICDB/94602824
 AB    HIV-NHL patients have an estimated survival according to authors between
       5-9 months, a better survival can be obtained in patients with a good
       performance status (PS), CD4 count greater than 100 ul/mm3 and without
       AIDS. Main causes of death are lymphoma, opportunistic infections and
       therapy toxicity. In order to reduce AIDS-related mortality and maintain
       the intended dose of chemotherapy, a phase II study was undertaken using
       the intensive induction chemotherapy regimen LNH84 (Am J Med 95:188-96,
       1993) with low-dose of zidovudine (5 mg/kg/day) and Gm-CSF (5 ug/kg/day;
       Schering-Plough). Thirty-two patients were included and their
       characteristics were histology-high grade lymphoma: 19 (15 Burkitt);
       intermediate grade: 13; stage III-IV: 19; extranodal sites greater than
       or equal to 2: 14 (marrow 5); LDH greater than 1N: 20; PS greater than
       or equal to 2: 7; CD4 less than or equal to 100: 12; prior AIDS: 4.
       Complete response (CR) occurred in 16 patients (50%) and partial
       response in 3, while 7 (22%) died during induction. Intended dose
       intensity was greater than 70% in 16 (57%) and less than or equal to 70%
       in 12. Six patients had long-lasting hematological toxicity. Among the
       16 CR, 5 relapsed. Overall survival was poor (6 months). No reduction of
       AIDS mortality was observed. Hematological toxicity of both chemotherapy
       and zidovudine is insufficiently reduced with Gm-CSF.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY
       Bleomycins/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  Combined Modality
       Therapy  Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Dose-Response Relationship, Drug  Doxorubicin/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  Drug Administration Schedule  Follow-Up Studies
       Granulocyte-Macrophage Colony-Stimulating Factor/*ADMINISTRATION  &
       DOSAGE/ADVERSE EFFECTS  Human  Lymphoma, AIDS-Related/*DRUG
       THERAPY/MORTALITY  Prednisolone/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Survival Rate  Vindesine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Zidovudine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).